RU2223753C2 - Способы модулирования функции серин/треонин протеинкиназы соединениями на основе 5-азахиноксалина, способ идентификации соединений, модулирующих функцию серин/треонин протеинкиназы, способ профилактики или лечения патологического состояния организма, фармацевтическая композиция, соединение на основе 5-азахиноксалина и способ его синтеза - Google Patents
Способы модулирования функции серин/треонин протеинкиназы соединениями на основе 5-азахиноксалина, способ идентификации соединений, модулирующих функцию серин/треонин протеинкиназы, способ профилактики или лечения патологического состояния организма, фармацевтическая композиция, соединение на основе 5-азахиноксалина и способ его синтеза Download PDFInfo
- Publication number
- RU2223753C2 RU2223753C2 RU2000111434/15A RU2000111434A RU2223753C2 RU 2223753 C2 RU2223753 C2 RU 2223753C2 RU 2000111434/15 A RU2000111434/15 A RU 2000111434/15A RU 2000111434 A RU2000111434 A RU 2000111434A RU 2223753 C2 RU2223753 C2 RU 2223753C2
- Authority
- RU
- Russia
- Prior art keywords
- group
- alkyl
- independently selected
- residues
- membered aryl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 37
- 150000001875 compounds Chemical class 0.000 title claims abstract 28
- 102100030011 Endoribonuclease Human genes 0.000 title claims abstract 18
- 101710199605 Endoribonuclease Proteins 0.000 title claims abstract 18
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 title claims abstract 18
- 230000001575 pathological effect Effects 0.000 title claims abstract 6
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract 3
- 238000011282 treatment Methods 0.000 title claims abstract 3
- 238000011321 prophylaxis Methods 0.000 title abstract 2
- 230000015572 biosynthetic process Effects 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 230000000694 effects Effects 0.000 claims abstract 8
- 125000000217 alkyl group Chemical group 0.000 claims 35
- 125000003118 aryl group Chemical group 0.000 claims 33
- 125000001072 heteroaryl group Chemical group 0.000 claims 29
- 125000001424 substituent group Chemical group 0.000 claims 29
- 229910052736 halogen Inorganic materials 0.000 claims 26
- 150000002367 halogens Chemical group 0.000 claims 26
- 229910052739 hydrogen Inorganic materials 0.000 claims 22
- 239000001257 hydrogen Substances 0.000 claims 22
- 150000002148 esters Chemical group 0.000 claims 20
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 17
- 125000004953 trihalomethyl group Chemical group 0.000 claims 16
- 229920006395 saturated elastomer Polymers 0.000 claims 15
- 125000004417 unsaturated alkyl group Chemical group 0.000 claims 15
- 150000007942 carboxylates Chemical group 0.000 claims 13
- 150000002431 hydrogen Chemical class 0.000 claims 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 12
- 125000003545 alkoxy group Chemical group 0.000 claims 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 8
- YEYHFKBVNARCNE-UHFFFAOYSA-N pyrido[2,3-b]pyrazine Chemical compound N1=CC=NC2=CC=CN=C21 YEYHFKBVNARCNE-UHFFFAOYSA-N 0.000 claims 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 6
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 6
- 239000003153 chemical reaction reagent Substances 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 239000001301 oxygen Substances 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 239000000758 substrate Substances 0.000 claims 6
- 150000001412 amines Chemical class 0.000 claims 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- 102000043136 MAP kinase family Human genes 0.000 claims 3
- 108091054455 MAP kinase family Proteins 0.000 claims 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 3
- 150000001299 aldehydes Chemical class 0.000 claims 3
- 150000001408 amides Chemical class 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 150000002576 ketones Chemical class 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 238000012544 monitoring process Methods 0.000 claims 3
- 239000000376 reactant Substances 0.000 claims 3
- 150000003457 sulfones Chemical class 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 239000011593 sulfur Substances 0.000 claims 3
- BVQVLAIMHVDZEL-UHFFFAOYSA-N 1-phenyl-1,2-propanedione Chemical compound CC(=O)C(=O)C1=CC=CC=C1 BVQVLAIMHVDZEL-UHFFFAOYSA-N 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 239000003054 catalyst Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 230000003993 interaction Effects 0.000 claims 2
- 239000006166 lysate Substances 0.000 claims 2
- 230000000771 oncological effect Effects 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 238000001179 sorption measurement Methods 0.000 claims 2
- MTMONFVFAYLRSG-UHFFFAOYSA-N 2-(4-hydroxyphenyl)-2-oxoacetaldehyde Chemical compound OC1=CC=C(C(=O)C=O)C=C1 MTMONFVFAYLRSG-UHFFFAOYSA-N 0.000 claims 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- WERABQRUGJIMKQ-UHFFFAOYSA-N 6-chloro-3-nitropyridin-2-amine Chemical compound NC1=NC(Cl)=CC=C1[N+]([O-])=O WERABQRUGJIMKQ-UHFFFAOYSA-N 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 239000007868 Raney catalyst Substances 0.000 claims 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical group [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 claims 1
- 229910000564 Raney nickel Inorganic materials 0.000 claims 1
- 206010048218 Xeroderma Diseases 0.000 claims 1
- 125000003158 alcohol group Chemical group 0.000 claims 1
- WURBFLDFSFBTLW-UHFFFAOYSA-N benzil Chemical group C=1C=CC=CC=1C(=O)C(=O)C1=CC=CC=C1 WURBFLDFSFBTLW-UHFFFAOYSA-N 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000003197 catalytic effect Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 239000003638 chemical reducing agent Substances 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 206010021198 ichthyosis Diseases 0.000 claims 1
- 238000011534 incubation Methods 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- LJDZFAPLPVPTBD-UHFFFAOYSA-N nitroformic acid Chemical group OC(=O)[N+]([O-])=O LJDZFAPLPVPTBD-UHFFFAOYSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 238000001308 synthesis method Methods 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6112397P | 1997-10-06 | 1997-10-06 | |
| US60/061,123 | 1997-10-06 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2000111434A RU2000111434A (ru) | 2002-02-27 |
| RU2223753C2 true RU2223753C2 (ru) | 2004-02-20 |
Family
ID=22033733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2000111434/15A RU2223753C2 (ru) | 1997-10-06 | 1998-10-05 | Способы модулирования функции серин/треонин протеинкиназы соединениями на основе 5-азахиноксалина, способ идентификации соединений, модулирующих функцию серин/треонин протеинкиназы, способ профилактики или лечения патологического состояния организма, фармацевтическая композиция, соединение на основе 5-азахиноксалина и способ его синтеза |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US6180631B1 (https=) |
| EP (1) | EP1028729B1 (https=) |
| JP (1) | JP2001518496A (https=) |
| KR (1) | KR100633270B1 (https=) |
| CN (1) | CN1169527C (https=) |
| AR (1) | AR013542A1 (https=) |
| AT (1) | ATE336250T1 (https=) |
| AU (1) | AU757585B2 (https=) |
| BG (1) | BG64969B1 (https=) |
| BR (1) | BR9814814A (https=) |
| CA (1) | CA2306257C (https=) |
| CY (1) | CY1106223T1 (https=) |
| CZ (1) | CZ298775B6 (https=) |
| DE (1) | DE69835612T2 (https=) |
| DK (1) | DK1028729T3 (https=) |
| ES (1) | ES2268791T3 (https=) |
| HU (1) | HUP0100302A3 (https=) |
| IL (2) | IL135103A0 (https=) |
| MX (1) | MXPA03011007A (https=) |
| NO (1) | NO316598B1 (https=) |
| NZ (1) | NZ503431A (https=) |
| PL (1) | PL192039B1 (https=) |
| PT (1) | PT1028729E (https=) |
| RU (1) | RU2223753C2 (https=) |
| SK (1) | SK4722000A3 (https=) |
| TR (2) | TR200000906T2 (https=) |
| TW (1) | TWI245765B (https=) |
| UA (1) | UA71555C2 (https=) |
| WO (1) | WO1999017759A2 (https=) |
| ZA (1) | ZA988961B (https=) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA71555C2 (en) | 1997-10-06 | 2004-12-15 | Zentaris Gmbh | Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| ATE538794T1 (de) * | 1999-01-13 | 2012-01-15 | Bayer Healthcare Llc | Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer |
| WO2001032658A1 (en) * | 1999-11-02 | 2001-05-10 | Ajinomoto Co., Inc. | Polyazanaphthalene compound and medicinal use thereof |
| US7371763B2 (en) * | 2001-04-20 | 2008-05-13 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
| US20080108672A1 (en) * | 2002-01-11 | 2008-05-08 | Bernd Riedl | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors |
| MXPA04007832A (es) | 2002-02-11 | 2005-09-08 | Bayer Pharmaceuticals Corp | Aril-ureas con actividad inhibitoria de angiogenesis. |
| AU2003270727A1 (en) * | 2002-09-17 | 2004-04-08 | Luna Innovations, Inc. | Remote temperature sensing of small volume and related apparatus thereof |
| US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
| WO2004113274A2 (en) * | 2003-05-20 | 2004-12-29 | Bayer Pharmaceuticals Corporation | Diaryl ureas with kinase inhibiting activity |
| DE10323345A1 (de) * | 2003-05-23 | 2004-12-16 | Zentaris Gmbh | Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren |
| DE102004022383A1 (de) * | 2004-05-06 | 2005-12-01 | Zentaris Gmbh | Neue Pyridopyrazine und deren Verwendung als Modulatoren von Kinasen |
| AU2004240747B2 (en) | 2003-05-23 | 2008-01-03 | Zentaris Gmbh | Novel pyridopyrazines and use thereof as kinase modulators |
| AU2004246800B2 (en) * | 2003-06-13 | 2008-12-04 | Novartis Ag | 2-aminopyrimidine derivatives as Raf kinase inhibitors |
| EA010485B1 (ru) | 2003-07-23 | 2008-10-30 | Байер Фамэсьютиклс Копэрейшн | Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты) |
| AU2006313701B2 (en) | 2005-11-11 | 2012-05-31 | Aeterna Zentaris Gmbh | Novel pyridopyrazines and their use as modulators of kinases |
| US8217042B2 (en) | 2005-11-11 | 2012-07-10 | Zentaris Gmbh | Pyridopyrazines and their use as modulators of kinases |
| EP1790342A1 (de) | 2005-11-11 | 2007-05-30 | Zentaris GmbH | Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege |
| WO2010003308A1 (zh) * | 2008-07-10 | 2010-01-14 | 卞化石 | 一氧化氮及其信息传递系统在制备恶性肿瘤靶向治疗药物中的应用 |
| GB0812969D0 (en) | 2008-07-15 | 2008-08-20 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| EP2508184A1 (en) | 2011-04-06 | 2012-10-10 | Æterna Zentaris GmbH | Pyridopyrazine derivatives and their use |
| GB201118656D0 (en) * | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118654D0 (en) * | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
| GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| RU2655604C2 (ru) | 2013-01-11 | 2018-05-29 | Фуджифилм Корпорэйшн | Азотсодержащее гетероциклическое соединение или его соль |
| GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
| DE102013008118A1 (de) * | 2013-05-11 | 2014-11-13 | Merck Patent Gmbh | Arylchinazoline |
| JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
| MX373150B (es) | 2014-03-26 | 2020-04-21 | Astex Therapeutics Ltd | Combinaciones de un inhibidor del factor de crecimiento de fibroblasto (fgfr) y un inhibidor del receptor del factor de crecimiento 1 similar a insulina (igf1r). |
| JP6752715B2 (ja) | 2014-03-26 | 2020-09-09 | アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | 組合せ |
| RU2743074C2 (ru) | 2014-08-01 | 2021-02-15 | Нуэволюшон А/С | Соединения, активные по отношению к бромодоменам |
| TWI719960B (zh) | 2015-02-10 | 2021-03-01 | 英商阿斯迪克治療公司 | 新穎組成物 |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| DK3353177T3 (da) | 2015-09-23 | 2020-08-24 | Janssen Pharmaceutica Nv | Tricykliske heterocykler til behandling af cancer |
| AU2016328693B2 (en) | 2015-09-23 | 2021-03-11 | Janssen Pharmaceutica Nv | Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer |
| US12012394B2 (en) * | 2018-02-19 | 2024-06-18 | Washington University | Alpha-synuclein ligands |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5217999A (en) * | 1987-12-24 | 1993-06-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Styryl compounds which inhibit EGF receptor protein tyrosine kinase |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4001017A (en) * | 1972-12-05 | 1977-01-04 | Ciba-Geigy Ag | Process for the photopolymerization of ethylenically unsaturated compounds |
| US4043819A (en) * | 1974-06-11 | 1977-08-23 | Ciba-Geigy Ag | Photo-polymerizable material for the preparation of stable polymeric images and process for making them by photopolymerization in a matrix |
| DE3804990A1 (de) * | 1988-02-18 | 1989-08-31 | Basf Ag | Herbizid wirksame, heterocyclisch substituierte sulfonamide |
| FR2656606B1 (fr) * | 1989-12-28 | 1993-06-25 | Roussel Uclaf | Utilisation de derives du 9,10-dihydrophenanthrene pour la preparation d'un medicament anti-tumoral, application a titre de medicaments de derives du 9,10-dihydrophenanthrene et produits derives de cette structure. |
| DE69105495T2 (de) | 1990-04-02 | 1995-04-06 | Pfizer | Benzylphosphonsäure-tyrosinkinaseinhibitoren. |
| US5302606A (en) | 1990-04-16 | 1994-04-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase |
| US5409930A (en) | 1991-05-10 | 1995-04-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| EP0586608A1 (en) | 1991-05-29 | 1994-03-16 | Pfizer Inc. | Tricyclic polyhydroxylic tyrosine kinase inhibitors |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| WO1994003427A1 (en) | 1992-08-06 | 1994-02-17 | Warner-Lambert Company | 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties |
| US5330992A (en) | 1992-10-23 | 1994-07-19 | Sterling Winthrop Inc. | 1-cyclopropyl-4-pyridyl-quinolinones |
| GB9226855D0 (en) | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
| US5700823A (en) * | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
| GB9501567D0 (en) | 1995-01-26 | 1995-03-15 | Pharmacia Spa | Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors |
| US5593997A (en) * | 1995-05-23 | 1997-01-14 | Pfizer Inc. | 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| US5723462A (en) * | 1996-04-26 | 1998-03-03 | Neurogen Corporation | Certain fused pyrrolecarboxamides a new class of GABA brain receptor ligands |
| UA71555C2 (en) | 1997-10-06 | 2004-12-15 | Zentaris Gmbh | Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives |
| GB9726851D0 (en) * | 1997-12-19 | 1998-02-18 | Zeneca Ltd | Human signal transduction serine/threonine kinase |
-
1998
- 1998-05-10 UA UA2000052578A patent/UA71555C2/uk unknown
- 1998-10-01 ZA ZA9808961A patent/ZA988961B/xx unknown
- 1998-10-05 PL PL339860A patent/PL192039B1/pl not_active IP Right Cessation
- 1998-10-05 TR TR2000/00906T patent/TR200000906T2/xx unknown
- 1998-10-05 CA CA002306257A patent/CA2306257C/en not_active Expired - Fee Related
- 1998-10-05 EP EP98948606A patent/EP1028729B1/en not_active Expired - Lifetime
- 1998-10-05 US US09/166,723 patent/US6180631B1/en not_active Expired - Fee Related
- 1998-10-05 AU AU95141/98A patent/AU757585B2/en not_active Ceased
- 1998-10-05 DK DK98948606T patent/DK1028729T3/da active
- 1998-10-05 JP JP2000514630A patent/JP2001518496A/ja not_active Withdrawn
- 1998-10-05 AT AT98948606T patent/ATE336250T1/de not_active IP Right Cessation
- 1998-10-05 KR KR1020007003656A patent/KR100633270B1/ko not_active Expired - Fee Related
- 1998-10-05 BR BR9814814-1A patent/BR9814814A/pt not_active Application Discontinuation
- 1998-10-05 CN CNB988099403A patent/CN1169527C/zh not_active Expired - Fee Related
- 1998-10-05 MX MXPA03011007A patent/MXPA03011007A/es not_active IP Right Cessation
- 1998-10-05 TR TR2001/00385T patent/TR200100385T2/xx unknown
- 1998-10-05 NZ NZ503431A patent/NZ503431A/en unknown
- 1998-10-05 SK SK472-2000A patent/SK4722000A3/sk unknown
- 1998-10-05 PT PT98948606T patent/PT1028729E/pt unknown
- 1998-10-05 CZ CZ20001129A patent/CZ298775B6/cs not_active IP Right Cessation
- 1998-10-05 IL IL13510398A patent/IL135103A0/xx not_active IP Right Cessation
- 1998-10-05 RU RU2000111434/15A patent/RU2223753C2/ru not_active IP Right Cessation
- 1998-10-05 WO PCT/US1998/020910 patent/WO1999017759A2/en not_active Ceased
- 1998-10-05 HU HU0100302A patent/HUP0100302A3/hu not_active Application Discontinuation
- 1998-10-05 ES ES98948606T patent/ES2268791T3/es not_active Expired - Lifetime
- 1998-10-05 DE DE69835612T patent/DE69835612T2/de not_active Expired - Fee Related
- 1998-10-06 AR ARP980104970A patent/AR013542A1/es unknown
- 1998-10-06 TW TW087116559A patent/TWI245765B/zh not_active IP Right Cessation
-
2000
- 2000-03-15 IL IL135103A patent/IL135103A/en unknown
- 2000-04-05 NO NO20001748A patent/NO316598B1/no unknown
- 2000-04-28 BG BG104392A patent/BG64969B1/bg unknown
- 2000-10-16 US US09/688,199 patent/US6727252B1/en not_active Expired - Fee Related
-
2006
- 2006-10-30 CY CY20061101554T patent/CY1106223T1/el unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5217999A (en) * | 1987-12-24 | 1993-06-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Styryl compounds which inhibit EGF receptor protein tyrosine kinase |
Non-Patent Citations (1)
| Title |
|---|
| O.JANYA et al. "Novel α-Amina-3-hydroxy-5-metilis.." J. Med. Chem., 1996, v.39, (6), p.1331-1338. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2223753C2 (ru) | Способы модулирования функции серин/треонин протеинкиназы соединениями на основе 5-азахиноксалина, способ идентификации соединений, модулирующих функцию серин/треонин протеинкиназы, способ профилактики или лечения патологического состояния организма, фармацевтическая композиция, соединение на основе 5-азахиноксалина и способ его синтеза | |
| RU2000111434A (ru) | Способы модулирования функции серин/треонин протеинкиназы соединениями на основе 5-азахиноксалина, способ идентификации соединений, модулирующих функцию серин/треонин протеинкиназы, способ профилактики или лечения патологического состояния организма, фармацевтическая композиция, соединение на основе 5-азахиноксалина и способ его синтеза | |
| RU2000110736A (ru) | Способ модулирования функции серин/треонин протеинкиназы соединением на основе азабензимидазола, способ идентификации соединений, модулирующих функцию серин/треонин протеинкиназы, способ профилактики или лечения патологических состояний в организме, соединение на основе азабензимидазола, способ его синтеза и фармацевтическая композиция | |
| Halloran et al. | Recent applications of diazirines in chemical proteomics | |
| Arai et al. | Kinetic resolution of amines by a nonenzymatic acylation catalyst | |
| Niks et al. | Allostery and substrate channeling in the tryptophan synthase bienzyme complex: evidence for two subunit conformations and four quaternary states | |
| Yu et al. | Elucidating the reaction pathway of decarboxylation-assisted olefination catalyzed by a mononuclear non-heme iron enzyme | |
| JP2001518496A5 (https=) | ||
| Jiao et al. | Enantioselective Strecker Reactions between Aldimines and Trimethylsilyl Cyanide Promoted by Chiral N, N′‐Dioxides | |
| Gramüller et al. | Tilting the Balance: London Dispersion Systematically Enhances Enantioselectivities in Brønsted Acid Catalyzed Transfer Hydrogenation of Imines | |
| Bedia et al. | Synthesis of a novel ceramide analogue and its use in a high‐throughput fluorogenic assay for ceramidases | |
| Cheng et al. | From Natural Product‐Inspired Pyrrolidine Scaffolds to the Development of New Human Golgi α‐Mannosidase II Inhibitors | |
| Schwarz et al. | Sulfamates of methyl triterpenoates are effective and competitive inhibitors of carbonic anhydrase II | |
| De Montellano et al. | Chiral orientation of prosthetic heme in the cytochrome P-450 active site. | |
| Lai et al. | Synthesis and protein kinase C inhibitory activities of balanol analogs with replacement of the perhydroazepine moiety | |
| Dalaigh et al. | Asymmetric acyl-transfer promoted by readily assembled chiral 4-N, N-dialkylaminopyridine derivatives | |
| Abdoli et al. | Inhibition studies on carbonic anhydrase isoforms I, II, IX, and XII with a series of sulfaguanidines | |
| Türker et al. | The (NHC) PdBr2 (2-aminopyridine) complexes: synthesis, characterization, molecular docking study, and inhibitor effects on the human serum carbonic anhydrase and serum bovine xanthine oxidase | |
| Yapar et al. | Exploring the potency of diazo‐coumarin containing hybrid molecules: Selective inhibition of tumor‐associated carbonic anhydrase isoforms IX and XII | |
| Guo et al. | Expanding the Rubterolone Family: Intrinsic Reactivity and Directed Diversification of PKS‐derived Pyrans | |
| Yusoff et al. | Design, synthesis and cholinesterase inhibitory activity of new dispiro pyrrolidine derivatives | |
| Durini et al. | SupraBox: Chiral supramolecular oxazoline ligands | |
| Abdoli et al. | Synthesis and Carbonic Anhydrase I, II, IX, and XII Inhibition Studies with a Series of Cyclic Sulfonyl Guanidines | |
| Martin et al. | N G-Aminoguanidines from Primary Amines and the Preparation of Nitric Oxide Synthase Inhibitors | |
| Oda et al. | Lewis Acid‐Catalyzed Nucleophilic Substitutions of Benzylic Alcohols with Sulfamides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20081006 |